Skip to main content
. Author manuscript; available in PMC: 2014 Apr 25.
Published in final edited form as: Circulation. 2012 May 8;125(23):2863–2872. doi: 10.1161/CIRCULATIONAHA.111.089169

Table 3.

Description of Intervention Processes

N (%) or Mean ± SD
Pharmacist level
    Patients activated over the entire intervention period 1797
    Patients having at least one encounter with the pharmacist 945 (52.6% of activated)
Patient level
    Encounters during 1st enrollment, (median) 3.8 ± 3.2 (3)
    Days enrolled during 1st enrollment, (median) 62 ±71 (41)
    Enrolled in the program more than once during intervention 35 (3.7)
    Encounters over entire intervention period, (median) 3.9 ±3.3 (3)
    Days enrolled over entire intervention period, (median) 64 ± 71 (42)
    Discharged at the 1st encounter 184 (19.5)
    Reasons for discharge (examining a patient's first discharge in the program)
        Had a target BP (Clinic or home) 650 (68.8)
        Lost to follow-up (e.g., no-showed for 3 encounters) or enrolled for 6+ months and no further progress was being made 97 (10.3)
        Program ended (i.e., 14 month intervention ended) 74 (7.8)
        Declined further participation 50 (5.3)
        DBP<60 46 (4.9)
        On maximum medications 22 (2.3)
        DBP<60 and on maximum medications 2 (0.2)
        Other 4 (0.4)
Encounter level
    Length of intake encounters (minutes), (median)* 50.2 ± 7.9 (52)
    Length of follow-up encounters (minutes), (median)* 26.9 ± 4.7 (28)
    Phone encounters (not Office) 2241 (60.8)
*

From pharmacist daily logs; collected during four different weeks over the intervention period